LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Turton, James A"
  2. AU="Patel, Abhijit A"
  3. AU="Shankowsky, Heather A"
  4. AU="Płóciennik, Przemysław"
  5. AU="Marchesi, Pietro"
  6. AU="Kim Je Hyoung"
  7. AU="Huber, Ingrid"
  8. AU="Hasuko, K."
  9. AU="Yao, Weigen"
  10. AU="Huang, Xiao-Fan"
  11. AU=Zuo Chuantian
  12. AU="Varchetta, Veronica"
  13. AU="Zhang, Lingye"
  14. AU="Venko, Katja"
  15. AU="Kasthuri, Thirupathi"
  16. AU="Pirtskhalava, Tamar"
  17. AU="Saridakis, E N"
  18. AU="Vithana, Eranga N"
  19. AU="Suárez-Lledó, M"
  20. AU="Olivo-Marston, Susan"
  21. AU="Denise P Momesso"
  22. AU="Obrecht-Sturm, Denise"

Search results

Result 1 - 5 of total 5

Search options

  1. Article: The inflammatory basis of exercise-induced bronchoconstriction.

    Brannan, John D / Turton, James A

    The Physician and sportsmedicine

    2010  Volume 38, Issue 4, Page(s) 67–73

    Abstract: Exercise-induced bronchoconstriction (EIB) is common in individuals with asthma, and may be observed even in the absence of a clinical diagnosis of asthma. Exercise-induced bronchoconstriction can be diagnosed via standardized exercise protocols, and ... ...

    Abstract Exercise-induced bronchoconstriction (EIB) is common in individuals with asthma, and may be observed even in the absence of a clinical diagnosis of asthma. Exercise-induced bronchoconstriction can be diagnosed via standardized exercise protocols, and anti-inflammatory therapy with inhaled corticosteroids (ICS) is often warranted. Exercise-related symptoms are commonly reported in primary care; however, access to standardized exercise protocols to assess EIB are often restricted because of the need for specialized equipment, as well as time constraints. Symptoms and lung function remain the most accessible indicators of EIB, yet these are poor predictors of its presence and severity. Evidence suggests that exercise causes the airways to narrow as a result of the osmotic and thermal consequences of respiratory water loss. The increase in airway osmolarity leads to the release of bronchoconstricting mediators (eg, histamine, prostaglandins, leukotrienes) from inflammatory cells (eg, mast cells and eosinophils). The objective assessment of EIB suggests the presence of airway inflammation, which is sensitive to ICS in association with a responsive airway smooth muscle. Surrogate tests for EIB, such as eucapnic voluntary hyperpnea or the osmotic challenge tests, cause airway narrowing via a similar mechanism, and a response indicates likely benefit from ICS therapy. The complete inhibition of EIB with ICS therapy in individuals with asthma may be a useful marker of control of airway pathology. Furthermore, inhibition of EIB provides additional, useful information regarding the identification of clinical control based on symptoms and lung function. This article explores the inflammatory basis of EIB in asthma as well as the effect of ICS on the pathophysiology of EIB.
    MeSH term(s) Adrenal Cortex Hormones/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Asthma, Exercise-Induced/drug therapy ; Asthma, Exercise-Induced/physiopathology ; Bronchoconstriction/physiology ; Bronchodilator Agents/therapeutic use ; Humans ; Inflammation/drug therapy ; Inflammation/physiopathology ; Inflammation Mediators/physiology ; Osmolar Concentration ; Respiratory Function Tests ; Water Loss, Insensible
    Chemical Substances Adrenal Cortex Hormones ; Anti-Inflammatory Agents ; Bronchodilator Agents ; Inflammation Mediators
    Language English
    Publishing date 2010-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 753046-8
    ISSN 2326-3660 ; 0091-3847
    ISSN (online) 2326-3660
    ISSN 0091-3847
    DOI 10.3810/psm.2010.12.1827
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Feasibility and acceptability of using bronchial hyperresponsiveness to manage asthma in primary care: a pilot study.

    Turton, James A / Glasgow, Nicholas J / Brannan, John D

    Primary care respiratory journal : journal of the General Practice Airways Group

    2011  Volume 21, Issue 1, Page(s) 28–34

    Abstract: Aims: To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care.: Methods: Fourteen adult patients with asthma aged 22-70 years (4M: ...

    Abstract Aims: To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care.
    Methods: Fourteen adult patients with asthma aged 22-70 years (4M:10F, forced expiratory volume in 1 s >70% predicted) taking ICS performed a test for BHR using mannitol on three visits 6 weeks apart. ICS dose adjustments were made based on the presence of BHR. The Asthma Quality of Life Questionnaire (AQLQ) and the Asthma Control Questionnaire were used at each visit. A semi structured interview at study exit assessed subject acceptability.
    Results: BHR did not return in those with no BHR at study entry (n=9) with decreasing ICS dose. Improvements in BHR with increasing ICS dose (n=5) were observed with clinically significant improvements in AQLQ (mean score increase >0.5, p=0.02). Feasibility and acceptability of BHR testing was demonstrated.
    Conclusions: It is feasible and acceptable to perform BHR testing using mannitol to help identify patients with asthma who would benefit from ICS dose increases and those with no BHR who could have a dose reduction.
    Trial registration: Australia New Zealand Clinical Trial Registry ACTRN12610000807055.
    MeSH term(s) Administration, Inhalation ; Adult ; Aged ; Anti-Inflammatory Agents/therapeutic use ; Asthma/classification ; Asthma/drug therapy ; Bronchial Hyperreactivity/drug therapy ; Bronchial Provocation Tests/methods ; Bronchoconstrictor Agents ; Feasibility Studies ; Female ; Forced Expiratory Volume/drug effects ; Humans ; Male ; Mannitol ; Middle Aged ; Pilot Projects ; Primary Health Care/methods ; Treatment Outcome
    Chemical Substances Anti-Inflammatory Agents ; Bronchoconstrictor Agents ; Mannitol (3OWL53L36A)
    Language English
    Publishing date 2011-09-21
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2129033-7
    ISSN 1475-1534 ; 1475-1534
    ISSN (online) 1475-1534
    ISSN 1475-1534
    DOI 10.4104/pcrj.2011.00079
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Psoriasis vulgaris flare during efalizumab therapy does not preclude future use

    Krueger James G / Turton James A / Lowes Michelle A / Barnetson Ross

    BMC Dermatology, Vol 5, Iss 1, p

    a case series

    2005  Volume 9

    Abstract: Abstract Background Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. Case presentations We present two patients with severe chronic plaque psoriasis who received ... ...

    Abstract Abstract Background Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. Case presentations We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-α). Conclusion These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.
    Keywords Dermatology ; RL1-803 ; Medicine ; R ; DOAJ:Dermatology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 616 ; 610
    Language English
    Publishing date 2005-08-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.

    Lowes, Michelle A / Turton, James A / Krueger, James G / Barnetson, Ross St C

    BMC dermatology

    2005  Volume 5, Page(s) 9

    Abstract: Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today.: Case presentations: We present two patients with severe chronic plaque psoriasis who received ... ...

    Abstract Background: Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today.
    Case presentations: We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienced a flare of their disease after missing a dose. However, after disease stablization, both patients responded well to re-introduction of efalizumab, one patient requiring concurrent treatment with infliximab (anti-TNF-alpha).
    Conclusion: These cases are presented to characterize this "flare" reaction, and to inform health care providers that efalizumab can still be administered after disease flare, and again may be a successful therapy.
    MeSH term(s) Adult ; Antibodies, Monoclonal/therapeutic use ; Arthritis, Psoriatic/drug therapy ; CD11 Antigens ; Female ; Humans ; Immunologic Factors/therapeutic use ; Lymphocyte Function-Associated Antigen-1/immunology ; Male ; Middle Aged ; Patient Compliance ; Psoriasis/drug therapy ; Psoriasis/immunology ; Secondary Prevention
    Chemical Substances Antibodies, Monoclonal ; CD11 Antigens ; Immunologic Factors ; Lymphocyte Function-Associated Antigen-1 ; efalizumab (XX2MN88N5D)
    Language English
    Publishing date 2005-08-18
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 2059863-4
    ISSN 1471-5945 ; 1471-5945
    ISSN (online) 1471-5945
    ISSN 1471-5945
    DOI 10.1186/1471-5945-5-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Inhaled mannitol improves lung function in cystic fibrosis.

    Jaques, Anna / Daviskas, Evangelia / Turton, James A / McKay, Karen / Cooper, Peter / Stirling, Robert G / Robertson, Colin F / Bye, Peter T P / LeSouëf, Peter N / Shadbolt, Bruce / Anderson, Sandra D / Charlton, Brett

    Chest

    2008  Volume 133, Issue 6, Page(s) 1388–1396

    Abstract: Background: The airways in patients with cystic fibrosis (CF) are characterized by the accumulation of tenacious, dehydrated mucus that is a precursor for chronic infection, inflammation, and tissue destruction. The clearance of mucus is an integral ... ...

    Abstract Background: The airways in patients with cystic fibrosis (CF) are characterized by the accumulation of tenacious, dehydrated mucus that is a precursor for chronic infection, inflammation, and tissue destruction. The clearance of mucus is an integral component of daily therapy. Inhaled mannitol is an osmotic agent that increases the water content of the airway surface liquid, and improves the clearance of mucus with the potential to improve lung function and respiratory health. To this end, this study examined the efficacy and safety of therapy with inhaled mannitol over a 2-week period.
    Methods: This was a randomized, double-blind, placebo-controlled, crossover study. Thirty-nine subjects with mild-to-moderate CF lung disease inhaled 420 mg of mannitol or placebo twice daily for 2 weeks. Following a 2-week washout period, subjects were entered in the reciprocal treatment arm. Lung function, respiratory symptoms, quality of life, and safety were assessed.
    Results: Mannitol treatment increased FEV(1) from baseline by a mean of 7.0% (95% confidence interval [CI], 3.3 to 10.7) compared to placebo 0.3% (95% CI, - 3.4 to 4.0; p < 0.001). The absolute improvement with mannitol therapy was 121 mL (95% CI, 56.3 to 185.7), which was significantly more than that with placebo (0 mL; 95% CI, - 64.7 to 64.7). The forced expiratory flow in the middle half of the FVC increased by 15.5% (95% CI, - 6.5 to 24.6) compared to that with placebo (increase, 0.7%; 95% CI, - 8.3 to 9.7; p < 0.02). The safety profile of mannitol was adequate, and no serious adverse events related to treatment were observed.
    Conclusions: Inhaled mannitol treatment over a period of 2 weeks significantly improved lung function in patients with CF. Mannitol therapy was safe and well tolerated.
    Trial registration: (ClinicalTrials.gov) Identifier: NCT00455130.
    MeSH term(s) Administration, Inhalation ; Adolescent ; Adult ; Child ; Confidence Intervals ; Cross-Over Studies ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis/physiopathology ; Diuretics, Osmotic/administration & dosage ; Diuretics, Osmotic/adverse effects ; Diuretics, Osmotic/therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Mannitol/administration & dosage ; Mannitol/adverse effects ; Mannitol/therapeutic use ; Middle Aged ; Quality of Life ; Respiratory Function Tests ; Surveys and Questionnaires ; Treatment Outcome
    Chemical Substances Diuretics, Osmotic ; Mannitol (3OWL53L36A)
    Language English
    Publishing date 2008-06
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1378/chest.07-2294
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top